Celcuity
Business Services · Minnesota, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
16305 36th Ave N Ste 100, Minneapolis, M...Phone Number
(763) 392-0767Website
www.celcuity.comRevenue
-Stock Symbol
CELCIndustry
ZI Rank: 2
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
2
1
1
2
2
About Celcuity
Celcuity is a clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic and companion diagnostic strategy. The company's therapeutic efforts are focused on in-licensing and developing molecularly targeted therapies that address the same cancer driver its companion diagnostics can identify. Its CELsignia companion diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from already approved targeted therapies. Celcuity is headquartered in Minneapolis.Explore more
Celcuity Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Celcuity your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Celcuity launches new products
Congratulate Masked Content for being promoted to Masked Content at Celcuity
Click to see if Celcuity had a recent Job posting/layoffs
Earning: See what the market has to say on Celcuity recently announced quarterly report
Check if Celcuity has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Celcuity has new funding data
Check out if Celcuity is spiking on competitors!
Celcuity, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Celcuity
Find 2 more new buyers
Compare Similar Companies to Celcuity
Compare insights from companies similar to Celcuity, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$123.9M
51-200
Public
$547.1M
1994
JB
Jennifer BuellPresident and CEO of MiNK Therapeutics, Chairman, Executive Council At Agenus
Company Profile Activity
Activity Insights
Celcuity is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Celcuity is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Celcuity.
Celcuity financials insights
Gather financial insights about Celcuity, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Multiple Rounds
$31.1M
2020
Debt
$350K
2021
Stock Offering
$24M
2024
Debt
$62M
Celcuity Tech Stack
A closer look at the technologies used by Celcuity
Most Recent Scoops
Person-Based
Product Launch, Marketing Strategy
Person-Based
Product Launch, Pharmaceuticals
Person-Based
Pharmaceuticals
Person-Based
Pharmaceuticals
Person-Based
Medical Research, Pharmaceuticals
Celcuity News & Media
Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer
MINNEAPOLIS, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, today announced the submission of its supplemental New Drug Application (“sNDA”) to the U.S. Food and Drug Administration (“FDA”) for REVTORPYK™ (gedatolisib) for the treatment of patients with hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-”), locally adCelcuity Inc. (CELC) Q2 2026 Earnings Call Transcript
Celcuity Inc. (CELC) Q2 2026 Earnings Call August 13, 2026 4:30 PM EDTCompany ParticipantsJodi Sievers - Head of Investor Relations & Corporate...Celcuity Q2 Earnings Call Highlights
Celcuity (NASDAQ:CELC) said it remains on track to begin commercial shipments of REVTORPYK, its gedatolisib therapy for certain patients with advanced breast cancer, late in the third quarter of 2026 following its recent FDA approval. The FDA approved REVTORPYK in July in combination with fulvestraCelcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update
MINNEAPOLIS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced financial results for the second quarter ended June 30, 2026 and other recent business developments.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Celcuity
Sign Up For FreeTo access detailed company insights
Celcuity is a clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic and companion diagnostic strategy. The company's therapeutic efforts are focused on in-licensing and developing molecularly targeted therapies that address the same cancer driver its companion diagnostics can ident... Read More
